

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THE STUDY	1
SCOPE OF REPORT	1
METHODOLOGY	2
RELATED BCC STUDIES	2
ANALYSTS CREDENTIALS	2
BCC RESEARCH ONLINE SERVICES	3
DISCLAIMER	3
CHAPTER TWO: SUMMARY.....	4
<i>SUMMARY TABLE U.S. MARKET FOR NEW THERAPEUTICS AND DIAGNOSTICS FOR WOMEN’S DISORDERS BY SEGMENT, THROUGH 2013 (\$ MILLIONS)</i>	5
<i>SUMMARY FIGURE U.S. MARKET FORECAST FOR NEW THERAPEUTICS AND DIAGNOSTICS FOR WOMEN’S DISORDERS BY SEGMENT, 2006–2013 (\$ MILLIONS)</i>	5
CHAPTER THREE: INDUSTRY OVERVIEW.....	6
DEFINITION OF WOMEN’S DISORDERS	6
IMPORTANCE OF THE INDUSTRY AND DEMOGRAPHICS.....	6
<i>TABLE 1 ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND PROJECTIONS BY GENDER, 2000-2020 (YEARS)</i>	7
<i>FIGURE 1 ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND PROJECTIONS BY GENDER, 2000-2020 (YEARS)</i>	7
<i>TABLE 2 PROJECTED GLOBAL FEMALE POPULATION BY AGE, THROUGH 2030 (MILLIONS)</i>	8
<i>FIGURE 2 PROJECTED GLOBAL FEMALE POPULATION BY AGE, THROUGH 2030 (MILLIONS)</i>	8
<i>TABLE 3 PROJECTED UNITED STATES FEMALE POPULATION BY AGE, THROUGH 2030 (MILLIONS)</i>	9
<i>FIGURE 3 PROJECTED UNITED STATES FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)</i>	9
HISTORY OF THE INDUSTRY AND RESPONSE TO WOMEN’S HEALTHCARE NEEDS	10
REGULATORY ENVIRONMENT	11
EFFECTS OF AGING.....	12
<i>FIGURE 4 FEMALE LIKELIHOOD OF GETTING PREGNANT VERSUS INFERTILITY AS AGE PROGRESSES, 2008 (%)</i>	12
<i>FIGURE 4 (CONTINUED)</i>	13
CONTRACEPTIVE INSURANCE COVERAGE	13
<i>TABLE 4 INSURANCE COVERAGE OF CONTRACEPTIVES BY STATE</i>	15
CONTRACEPTIVE USE IN TEENS INCREASES	16
NEW USE FOR CONTRACEPTIVES	17

NEW USE FOR CONTRACEPTIVES (CONTINUED).....	18
AGING AND INFERTILITY	19
CONTRACEPTIVE PATCH LINKED TO DEATHS.....	20
WOMEN AND SEXUAL HEALTH.....	20
WOMEN AND SEXUAL HEALTH (CONTINUED).....	21
INCIDENCE OF SEXUAL DYSFUNCTION.....	22
Incidence of Sexual Dysfunction (Continued)	23
VASCULAR TREATMENTS AND SEXUAL DYSFUNCTION.....	24
DIAGNOSTICS	25
NEW DEVELOPMENTS IN SEXUAL DYSFUNCTION	
TREATMENTS FOR WOMEN	25
Alista	26
<i>TABLE 5 U.S. SEXUAL DYSFUNCTION PRODUCTS FOR WOMEN IN</i>	
<i>DEVELOPMENT, 2008.....</i>	<i>26</i>
SEXUAL DYSFUNCTION IN CANCER	26
INFERTILITY AND CANCER.....	27
CHEMOTHERAPY	27
RADIATION	28
PREVENTION STRATEGIES.....	28
MARKETING AND WOMEN.....	29
COUNTERFEIT PHARMACEUTICALS.....	29
GENERIC PARTICIPATION	30
<i>TABLE 6 U.S. PRESCRIPTION GENERIC DRUG APPROVALS FOR</i>	
<i>CONTRACEPTION BY COMPANY AND APPROVAL DATE, 2003–</i>	
<i>2008.....</i>	<i>30</i>
INTERNATIONAL ISSUES.....	31
CHAPTER FOUR: AUTOIMMUNE DISEASES	32
U.S. MARKET OVERVIEW	32
MARKET SIZE.....	33
<i>TABLE 7 U.S. MARKET FORECAST FOR AUTOIMMUNE DISEASES</i>	
<i>BY PRODUCT SEGMENT, THROUGH 2013 (\$ MILLIONS).....</i>	<i>33</i>
COMPETITIVE ANALYSIS	33
<i>TABLE 8 MANUFACTURERS OF AUTOIMMUNE DISEASE</i>	
<i>PRODUCTS, 2008.....</i>	<i>34</i>
<i>TABLE 9 U.S. SUMMARY OF AUTOIMMUNE DISEASE MARKET BY</i>	
<i>COMPETITOR REVENUES, 2008 (\$ MILLIONS)</i>	<i>34</i>
<i>FIGURE 5 U.S. SUMMARY OF AUTOIMMUNE DISEASE MARKET BY</i>	
<i>COMPETITOR REVENUES, 2008 (%).....</i>	<i>35</i>
MARKET BY DISEASE TYPE.....	35
CHRONIC FATIGUE SYNDROME.....	35
Incidence and Mortality	36
Market Indicators.....	36
Market Indicators (Continued).....	37
Market Indicators (Continued).....	38

FIBROMYALGIA	39
Incidence	39
Diagnostics	40
Pain in 11 of 18 Tender Point Sites on Digital	
Palpation	40
Pain in 11 of 18 ... (Continued)	41
Market Indicators	42
Market Indicators (Continued)	43
Current Market Participants	44
MYASTHENIA GRAVIS	44
Incidence and Mortality	45
Diagnostics	45
Market Indicators	46
Current Market Participants	47
SJOGREN'S SYNDROME	47
Incidence and Mortality	48
Diagnostics	48
Market Indicators	49
Current Market Participants	49
SYSTEMIC LUPUS ERYTHEMATOSUS	49
Systemic Lupus ... (Continued)	50
Incidence and Mortality	51
Diagnostics	52
Diagnostics (Continued)	53
Market Indicators	54
IN DEVELOPMENT	55
PRESTARA	55
AMPLIGEN	56
RIQUENT	56
ALL U.S. PRODUCTS IN DEVELOPMENT	56
<i>TABLE 10 U.S. AUTOIMMUNE DISEASE PRODUCTS IN</i>	
<i>DEVELOPMENT, 2008</i>	56
<i>TABLE 10 (CONTINUED)</i>	57
CHAPTER FIVE: WOMEN'S CANCERS	58
U.S. MARKET OVERVIEW	58
MARKET SIZE	58
<i>TABLE 11 U.S. MARKET FORECAST FOR WOMEN'S CANCER BY</i>	
<i>PRODUCT SEGMENT, THROUGH 2013 (\$ MILLIONS)</i>	59
COMPETITIVE ANALYSIS	59
<i>TABLE 12 MANUFACTURERS OF WOMEN'S CANCER PRODUCTS,</i>	
<i>2008</i>	60
<i>TABLE 13 SUMMARY OF CANCER MARKET BY COMPETITOR</i>	
<i>REVENUES, 2008 (\$ MILLIONS)</i>	61

FIGURE 6 SUMMARY OF CANCER MARKET BY COMPETITOR

<i>REVENUES, 2008 (%)</i>	61
MARKET BY TYPE OF CANCER	61
BREAST CANCER.....	61
<i>TABLE 14 TNM CLASSIFICATIONS OF BREAST CANCERS</i>	62
<i>TABLE 15 5-YEAR SURVIVAL RATE BASED ON STAGE OF BREAST CANCER FOR WOMEN IN THE U.S, 2008 (%)</i>	63
Incidence and Mortality	64
<i>TABLE 16 TOTAL YEARLY CASES AND DEATHS FOR BREAST CANCER IN WOMEN WORLDWIDE, 2008</i>	64
Diagnostics.....	64
Diagnostics (Continued)	65
Market Indicators	66
Market Indicators (Continued).....	67
Market Indicators (Continued).....	68
Market Indicators (Continued).....	69
Market Indicators (Continued).....	70
Current Market Participants	71
CERVICAL CANCER.....	71
Incidence and Mortality	72
Diagnostics.....	72
Market Indicators	73
Current Market Participants	74
ENDOMETRIAL CANCER	75
Incidence and Mortality	76
Market Indicators	76
Current Market Participants	77
OVARIAN CANCER	77
Incidence and Mortality	78
Diagnostics.....	78
Market Indicators	79
Market Indicators (Continued).....	80
Current Market Participants	81
IN DEVELOPMENT.....	81
572016.....	81
ACTIMMUNE.....	81
ARZOXIFENE	82
ATAMESTANE	82
FASLODEX	82
IMC-C2259.....	82
FABLYN	82
OVAREX.....	82
TEMSIROLIMUS.....	83
THERATOPE	83

OPAXIO	83
A FEW SELECT U.S. PRODUCTS IN DEVELOPMENT	84
<i>TABLE 17 SELECTED WOMEN'S CANCER PRODUCTS IN DEVELOPMENT IN THE U.S., 2008.....</i>	<i>84</i>
CHAPTER SIX: GYNECOLOGICAL INFECTIONS AND SEXUALLY TRANSMITTED DISEASES	
U.S. MARKET OVERVIEW	85
<i>TABLE 18 U.S. GYNECOLOGICAL DISEASES AND INFECTIONS.....</i>	<i>86</i>
MARKET SIZE.....	86
<i>TABLE 19 U.S. MARKET FORECAST FOR GYNECOLOGICAL DISEASES AND INFECTIONS BY PRODUCT SEGMENT, THROUGH 2013 (\$ MILLIONS).....</i>	<i>87</i>
COMPETITIVE ANALYSIS	87
<i>TABLE 20 U.S. GYNECOLOGICAL DISEASES AND INFECTIONS MARKET BY COMPETITOR REVENUE, 2008 (\$ MILLIONS).....</i>	<i>87</i>
<i>FIGURE 7 SUMMARY OF U.S. GYNECOLOGICAL DISEASES AND INFECTIONS MARKET BY COMPETITOR REVENUES, 2008 (%).....</i>	<i>88</i>
<i>TABLE 21 MANUFACTURERS OF GYNECOLOGICAL DISEASE AND INFECTION PRODUCTS, 2008.....</i>	<i>88</i>
<i>TABLE 21 (CONTINUED).....</i>	<i>89</i>
MARKET BY DISEASE TYPE.....	89
BACTERIAL VAGINOSIS	89
Incidence	89
Market Indicators	89
CANDIDIASIS.....	90
Incidence	91
Market Indicators	91
Current Market Participants	92
CERVICAL DYSPLASIA	92
Incidence	93
CHLAMYDIA	93
Incidence	94
Diagnostics.....	94
Market Indicators	95
CONDYLOMA.....	95
Incidence	96
Market Indicators	96
DYSMENORRHEA	97
Incidence	97
ENDOMETRIOSIS.....	97
Incidence	97
Market Indicators	98
FIBROIDS	99
Incidence	99

Market Indicators	99
GENITAL HERPES	100
Incidence	101
Diagnostics	101
Market Indicators	102
Current Market Participants	102
PELVIC INFLAMMATORY DISEASE	102
Incidence	103
Market Indicators	103
IN DEVELOPMENT	103
HUMAN PAPILLOMAVIRUS	104
LOW DOSE ORAL INTERFERON-ALPHA	104
ALL U.S. PRODUCTS IN DEVELOPMENT	104
<i>TABLE 22 GYNECOLOGICAL DISEASE AND INFECTION PRODUCTS</i> <i>IN DEVELOPMENT IN THE U.S., 2008</i>	104
<i>TABLE 22 (CONTINUED)</i>	105

CHAPTER SEVEN: KIDNEY AND UROLOGIC DISEASES AND

CONDITIONS	106
U.S. MARKET OVERVIEW	106
MARKET SIZE	106
<i>TABLE 23 U.S. MARKET FORECAST FOR KIDNEY AND</i> <i>UROLOGICAL DISEASES AND INFECTIONS BY PRODUCT</i> <i>SEGMENT, THROUGH 2013 (\$ MILLIONS)</i>	107
COMPETITIVE ANALYSIS	107
<i>TABLE 24 U.S. KIDNEY AND UROLOGICAL DISEASES AND</i> <i>INFECTION MARKET BY COMPETITOR REVENUE, 2008 (\$</i> <i>MILLIONS)</i>	108
<i>FIGURE 8 SUMMARY OF KIDNEY AND UROLOGICAL DISEASES</i> <i>AND INFECTION MARKET BY COMPETITOR REVENUES, 2008 (%)</i>	108
<i>TABLE 25 MANUFACTURERS OF KIDNEY AND UROLOGIC</i> <i>DISEASE AND CONDITION PRODUCTS, 2008</i>	109
MARKET BY DISEASE TYPE.....	109
URINARY TRACT INFECTIONS.....	109
Incidence	110
Diagnostics	110
Market Indicators	110
Market Indicators (Continued).....	111
URINARY INCONTINENCE	112
Incidence	113
Market Indicators	114
Current Market Participants	115
<i>TABLE 26 U.S. URINARY INCONTINENCE/OVERACTIVE BLADDER</i> <i>MARKET BY COMPETITOR REVENUE, 2008 (\$ MILLIONS)</i>	116
URINARY INTERSTITIAL CYSTITIS	116

Incidence	116
Market Size and Growth	116
IN DEVELOPMENT	117
ALL U.S. PRODUCTS IN DEVELOPMENT	117
<i>TABLE 27 KIDNEY AND UROLOGICAL DISEASE AND CONDITIONS</i>	
<i>PRODUCTS IN DEVELOPMENT IN THE U.S., 2008</i>	117
<i>TABLE 27 (CONTINUED)</i>	118
 CHAPTER EIGHT: REPRODUCTIVE-RELATED THERAPEUTICS AND	
DIAGNOSTICS.....	119
U.S. MARKET OVERVIEW	119
MARKET SIZE	119
<i>TABLE 28 U.S. MARKET FORECAST FOR REPRODUCTIVE-</i>	
<i>RELATED THERAPEUTICS AND DIAGNOSTICS BY PRODUCT</i>	
<i>SEGMENT, THROUGH 2013 (\$ MILLIONS)</i>	120
COMPETITIVE ANALYSIS	120
<i>TABLE 29 U.S. REPRODUCTIVE-RELATED THERAPEUTICS AND</i>	
<i>DIAGNOSTICS MARKET BY COMPETITOR REVENUE, 2008 (\$</i>	
<i>MILLIONS)</i>	121
<i>FIGURE 9 SUMMARY OF U.S. REPRODUCTIVE-RELATED</i>	
<i>THERAPEUTICS AND DIAGNOSTICS MARKET BY COMPETITOR</i>	
<i>REVENUES, 2008 (%)</i>	121
MARKET BY TYPE	121
CONTRACEPTION.....	121
<i>TABLE 30 CONTRACEPTIVE USE BY METHOD FOR U.S. WOMEN</i>	
<i>AGE 15 TO 44, BY RACE, 2002 (THOUSANDS)</i>	122
<i>FIGURE 10 CONTRACEPTIVE USE BY METHOD FOR U.S. WOMEN</i>	
<i>AGE 15 TO 44, BY RACE, 2002 (THOUSANDS)</i>	122
Market Indicators	123
Market Indicators (Continued).....	124
Market Indicators (Continued).....	125
Market Indicators (Continued).....	126
Market Indicators (Continued).....	127
Most Commonly Used Oral Contraceptives.....	128
<i>TABLE 31 MOST COMMONLY USED ORAL CONTRACEPTIVES IN</i>	
<i>THE U.S., 2008</i>	128
<i>TABLE 31 (CONTINUED)</i>	129
Most Commonly ... (Continued)	130
Current Market Participants	131
<i>TABLE 32 U.S. CONTRACEPTION MARKET BY COMPETITOR</i>	
<i>REVENUE, 2008 (\$ MILLIONS)</i>	132
INFERTILITY	132
Incidence	133
Market Indicators.....	133
Hormonal Therapy.....	134

Hormonal Therapy (Continued)	135
Surgical Treatment.....	136
Artificial Insemination	136
Assisted Reproductive Technology	137
Current Market Participants	137
<i>TABLE 33 U.S. INFERTILITY MARKET BY COMPETITOR REVENUE,</i>	
<i>2008 (\$ MILLIONS).....</i>	<i>137</i>
MENOPAUSE	138
Incidence	138
Market Indicators.....	138
Most Commonly Used Menopause Treatment	
Products	139
<i>TABLE 34 MOST COMMONLY USED MENOPAUSE TREATMENT</i>	
<i>PRODUCTS 2008.....</i>	<i>139</i>
Most Commonly ... (Continued).....	140
Current Market Participants	141
<i>TABLE 35 U.S. MENOPAUSE MARKET BY COMPETITOR REVENUE,</i>	
<i>2008 (\$ MILLIONS).....</i>	<i>142</i>
IN DEVELOPMENT.....	142
BAZEDOXIFENE/CONJUGATED ESTROGENS	142
ALL U.S. PRODUCTS IN DEVELOPMENT.....	142
<i>TABLE 36 REPRODUCTIVE-RELATED PRODUCTS IN</i>	
<i>DEVELOPMENT IN THE U.S., 2008.....</i>	<i>142</i>
<i>TABLE 36 (CONTINUED).....</i>	<i>143</i>
CHAPTER NINE: RHEUMATOID ARTHRITIS AND OSTEOPOROSIS.....	144
U.S. MARKET OVERVIEW	144
MARKET SIZE	144
<i>TABLE 37 U.S. MARKET FORECAST FOR RHEUMATOID ARTHRITIS</i>	
<i>AND OSTEOPOROSIS BY PRODUCT SEGMENT, THROUGH 2013</i>	
<i>(\$ MILLIONS).....</i>	<i>144</i>
COMPETITIVE ANALYSIS	145
<i>TABLE 38 U.S. RHEUMATOID ARTHRITIS AND OSTEOPOROSIS</i>	
<i>MARKET BY COMPETITOR REVENUE, 2008 (\$ MILLIONS).....</i>	<i>145</i>
<i>FIGURE 11 SUMMARY OF U.S. RHEUMATOID ARTHRITIS AND</i>	
<i>OSTEOPOROSIS MARKET BY COMPETITOR REVENUES, 2008 (%).....</i>	<i>146</i>
<i>TABLE 39 MANUFACTURERS OF RHEUMATOID ARTHRITIS AND</i>	
<i>OSTEOPOROSIS PRODUCTS, 2008.....</i>	<i>146</i>
<i>TABLE 39 (CONTINUED).....</i>	<i>147</i>
MARKET BY TYPE	147
RHEUMATOID ARTHRITIS.....	147
Incidence	148
Market Indicators.....	149
Aspirin and Other Nonsteroidal Anti-Inflammatory	
Drugs.....	149

Cox-2 Inhibitors	150
Disease-Modifying Anti-Rheumatic Drugs	150
Immunosuppressants	151
Corticosteroids	151
Tumor Necrosis Factor Blocker	151
B-lymphocyte-Restricted Differentiation Antigen (CD20) Inhibitor	152
Selective Costimulation Modulator	153
Current Market Participants	153
<i>TABLE 40 U.S. RHEUMATOID ARTHRITIS MARKET BY COMPETITOR REVENUE, 2008 (\$ MILLIONS)</i>	153
OSTEOPOROSIS	154
Incidence	154
Diagnostics	154
Diagnostics (Continued)	155
Market Indicators	156
Market Indicators (Continued).....	157
Current Market Participants	158
<i>TABLE 41 U.S. OSTEOPOROSIS MARKET BY COMPETITOR REVENUE, 2008 (\$ MILLIONS)</i>	158
IN DEVELOPMENT.....	158
PREXIGE.....	158
REMICADE	158
PREOS	159
ARZOXIFENE	159
FABLYN	159
U.S. PRODUCTS IN DEVELOPMENT	160
<i>TABLE 42 RHEUMATOID ARTHRITIS AND OSTEOPOROSIS PRODUCTS IN DEVELOPMENT IN U.S., 2008</i>	160
<i>TABLE 42 (CONTINUED)</i>	161
CHAPTER TEN: MARKET SUMMARY	162
U.S. WOMEN'S HEALTHCARE MARKET ANALYSIS	162
<i>TABLE 43 U.S. WOMEN'S HEALTHCARE DISORDER MARKET FORECAST BY SEGMENT, THROUGH 2013 (\$ MILLIONS)</i>	162
<i>FIGURE 12 U.S. WOMEN'S HEALTHCARE DISORDER MARKET FORECAST BY SEGMENT, THROUGH 2013 (\$ MILLIONS)</i>	163
CHAPTER ELEVEN: INDUSTRY PARTICIPANTS BY TYPE.....	164
<i>TABLE 44 MAJOR WOMEN'S HEALTHCARE INDUSTRY PARTICIPANTS, BY PRODUCT TYPE, 2008</i>	164
<i>TABLE 44 (CONTINUED)</i>	165
SELECTED COMPANY PROFILES	166
ASTRAZENECA.....	166
BARR LABORATORIES, INC.....	167

Barr Laboratories, Inc. (Continued)	168
BRISTOL-MYERS SQUIBB CO.....	169
ELI LILLY & CO.....	169
GENENTECH	170
GLAXOSMITHKLINE	170
MERCK & CO., INC.....	171
ORTHO-MCNEIL PHARMACEUTICALS.....	172
PFIZER	173
SERONO INTERNATIONAL S.A.	173
WYETH.....	174
LIST OF COMPANIES.....	175
LIST OF COMPANIES (CONTINUED).....	176
LIST OF COMPANIES (CONTINUED).....	177
LIST OF COMPANIES (CONTINUED).....	178
LIST OF COMPANIES (CONTINUED).....	179
LIST OF COMPANIES (CONTINUED).....	180
LIST OF COMPANIES (CONTINUED).....	181
LIST OF COMPANIES (CONTINUED).....	182
LIST OF COMPANIES (CONTINUED).....	183
LIST OF COMPANIES (CONTINUED).....	184
LIST OF COMPANIES (CONTINUED).....	185
LIST OF COMPANIES (CONTINUED).....	186
LIST OF COMPANIES (CONTINUED).....	187
LIST OF COMPANIES (CONTINUED).....	188
LIST OF COMPANIES (CONTINUED).....	189
LIST OF COMPANIES (CONTINUED).....	190
LIST OF COMPANIES (CONTINUED).....	191
LIST OF COMPANIES (CONTINUED).....	192
LIST OF COMPANIES (CONTINUED).....	193
LIST OF COMPANIES (CONTINUED).....	194
LIST OF COMPANIES (CONTINUED).....	195
LIST OF COMPANIES (CONTINUED).....	196
LIST OF COMPANIES (CONTINUED).....	197
LIST OF COMPANIES (CONTINUED).....	198